Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

81. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

2016 European Medicines Agency - EPARs

82. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223157 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096-7 10.1056/NEJMc1602599 Black Dennis M DM Rosen Clifford J CJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2095 27223158 N Engl J Med. 2016 May 26;374(21):2095-6 (...) 27223159 N Engl J Med. 2016 May 26;374(21):2096 27223160 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223157 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA4

2016 NEJM

83. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223158 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095 10.1056/NEJMc1602599 Michaëlsson Karl K Uppsala University, Uppsala, Sweden karl.michaelsson@surgsci.uu.se. Aspenberg Per P Linköping University, Linköping, Sweden. eng 88225-1 CIHR Canada Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med (...) . 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223158 10.1056/NEJMc1602599 PMC5104560 CAMS6243 10.1056/NEJMc1602599#SA1 N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 BMJ. 2015 May 26;350:h2088 26013536 Osteoporos Int. 2016 Jan;27(1):417

2016 NEJM

84. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223159 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095-6 10.1056/NEJMc1602599 Ott Susan M SM University of Washington, Seattle, WA smott@uw.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density (...) Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223159 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA2

2016 NEJM

85. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223160 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096 10.1056/NEJMc1602599 Cheung Angela M AM University of Toronto, Toronto, ON, Canada angela.cheung@uhn.ca. Papaioannou Alexandra A McMaster's University, Hamilton, ON, Canada. Morin Suzanne S McGill University, Montreal, QC, Canada. Osteoporosis Canada Scientific Advisory Council eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223160 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA3

2016 NEJM

86. Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis Full Text available with Trip Pro

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men.Serum Omentin-1, bone turnover biochemical markers, and bone mineral density (BMD) were determined in 45 older men with osteoporosis or 45 older men without osteoporosis (65-70 years old).Omentin-1 levels were increased in older men with osteoporosis, and the differences remained (...) with osteoporosis and control groups that were considered separately.Omentin-1 is an independent predictor of BMD in older men with osteoporosis, and it is negatively correlated with bone turnover biochemical markers. It is suggested that Omentin-1 may exert a negative effect on bone mass through the regulation of the osteoblast differentiation in the older men with osteoporosis.

2016 Chronic diseases and translational medicine

87. Osteoporosis Decision Aid

Osteoporosis Decision Aid Osteoporosis Decision Aid | Mayo Clinic Shared Decision Making National Resource Center Toggle navigation Osteoporosis Decision Aid The Osteoporosis Choice decision aid conveys the pros and cons of treatment It uses estimates of the patient's based on the FRAX calculator. Decision aids to be used during the encounter: interactive tool Printed version Decision aids in practice: Additional resources DISCLAIMER : No decision aid replaces the conversation patients should

2016 Washington Health Care Authority

88. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 22 (Suppl 4) September 2016 1 AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016 Pauline M. Camacho, MD, FACE; Steven M. Petak, MD, MACE (...) University Osteoporosis and Metabolic Bone Disease Center, Chicago, IL; 2 Associate Clinical Professor Weill-Cornell Medical College, Division Head Endocrinology and Chief of Endocrinology, Houston Methodist Hospital, Houston, TX; 3 School of Medicine and Public Health, University of Wisconsin, Madison, WI; 4 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN; 5 Clinical Professor of Medicine, University of California, San Francisco; 6 Division of Endocrinology

2016 American Association of Clinical Endocrinologists

89. Osteoporosis and Bone Mineral Density

Osteoporosis and Bone Mineral Density Date of origin: 1998 Last review date: 2016 ACR Appropriateness Criteria ® 1 Osteoporosis and Bone Mineral Density American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD screening or individuals with established or clinically suspected low BMD. 1. All women age 65 years and older and men age 70 years and older (asymptomatic screening) 2. Women younger than age 65 (...) years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include: a. Estrogen deficiency b. A history of maternal hip fracture that occurred after the age of 50 years c. Low body mass ( 1 year before age 42 years) 3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including: a. Current use of cigarettes b. Loss of height, thoracic kyphosis 4. Individuals of any age

2016 American College of Radiology

90. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Full Text available with Trip Pro

Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Informing evidence‐based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update - Ozel - 2016 - Developmental Medicine & Child Neurology - Wiley Online Library The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

2016 Pediatric Endocrine Society

91. Osteoporosis

Osteoporosis DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS Clinical Practice Guideline | February 2016 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians will understand who and how to screen, assess, diagnose, treat and manage osteoporosis and/or fracture risk. TARGET POPULATION (...) All men and women 50 years of age and older EXCLUSIONS All men and women under 50 years of age This guideline is partially adapted from Papaioannou A, Morin S, Cheung AM, et al; for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ. 2010;182:1864-73. 1 KEY MESSAGES ? The goal is to find patients at high risk of fracture, not just low bone mineral density (BMD) (see Algorithm). ? BMD

2016 Accelerating Change Transformation Team

92. High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women

High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women UTCAT2893, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women Clinical Question How does a high protein diet affect ridge resorption in women? Clinical Bottom Line A high protein diet coupled with a low calcium (...) intake can increase urinary losses of calcium and is linked to osteoporosis and ridge resorption in older women. This is supported by narrative reviews outlining observations of populations who maintain a high protein diet and a narrative review of studies showing the relationship between increased protein intake and increased levels of calcium lost in urine. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence

2015 UTHSCSA Dental School CAT Library

93. Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis

Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) in Osteoporosis: Clinical Effectiveness and Guidelines DATE: 04 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of repeat dual energy x-ray absorptiometry (DEXA) scans every two years in patients with osteoporosis or at risk for osteoporosis? 2. What are the evidence-based guidelines for DEXA in patients with osteoporosis or at risk for osteoporosis? KEY FINDINGS Two health technology assessments, one observational study, and eight evidence-based guidelines were identified regarding

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

94. Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women

Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women An online system shows promise for the early detection of osteoporosis in Asian women | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An online system shows promise for the early detection of osteoporosis in Asian women Article Text Adult nursing Cross-sectional study An online system shows promise for the early detection

2015 Evidence-Based Nursing

95. Management of Osteoporosis

Management of Osteoporosis Malaysian Osteoporosis Society Clinical Guidance on Management of Osteoporosis 2 0 12 Academy of Medicine Ministry of Health Malaysia MOH/P/PAK/345.17(GU) Second Edition (2015) 02 Published by: Malaysian Osteoporosis Society c/o No. 79, Jalan SS 23/15 Taman SEA, 47400 Petaling Jaya Selangor Darul Ehsan, Malaysia Endorsed by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 (...) Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is the Malaysia Osteoporosis Society (persatuan Osteoporosis Malaysia). Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to the Malaysia Osteoporosis Society is included and the content is not changed, not sold, nor used to promote or endorse any product or service, and not used in an inappropriate or misleading

2015 Ministry of Health, Malaysia

96. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2015 SIGN

97. Abaloparatide for postmenopausal osteoporosis ? first and second line

Abaloparatide for postmenopausal osteoporosis ? first and second line Abaloparatide for postmenopausal osteoporosis – first and second line Abaloparatide for postmenopausal osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Abaloparatide for postmenopausal osteoporosis – first (...) and second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Osteoporosis, Postmenopausal Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT

2014 Health Technology Assessment (HTA) Database.

98. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of raloxifene and bazedoxifene for postmenopausal women with osteoporosis, based on their fracture probability, in eight European countries. The authors concluded

2014 NHS Economic Evaluation Database.

99. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis Full Text available with Trip Pro

Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis Osteoporosis has previously been reported to be twice as common in patients with RA as in controls, but these studies predate the introduction of aggressive management of RA. The aim of this study was to evaluate the prevalence and clinical predictors of osteoporosis in RA in a contemporary cohort and to develop a clinical tool for the identification of patients at risk.The (...) prevalence of osteoporosis was related to clinical and demographic variables in 304 consecutive RA patients undergoing DXA at a single centre between 2009 and 2010 and compared with the frequency of osteoporosis in a population-based cohort of 903 subjects.The RA cohort was predominantly female (81.9%), with an average age of 63.5 years (s.d. 11.8) and a disease duration of 9.6 years (s.d. 10.2). Osteoporosis was present in 91 (29.9%) patients at either the spine or total hip compared with 157/903 (17.4

2014 EvidenceUpdates

100. Denosumab for glucocorticoid-induced osteoporosis

Denosumab for glucocorticoid-induced osteoporosis Denosumab for glucocorticoid-induced osteoporosis Denosumab for glucocorticoid-induced osteoporosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Denosumab for glucocorticoid-induced osteoporosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning (...) Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Diphosphonatess; Osteoporosis Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent

2014 Health Technology Assessment (HTA) Database.